Ciclosporin ophthalmic - Allergan

Drug Profile

Ciclosporin ophthalmic - Allergan

Alternative Names: Cyclosporin - Allergan; Cyclosporin ophthalmic emulsion; Cyclosporine - Allergan; Restasis; RESTASIS MULTIDOSE; Restasis X

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Allergan
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes

Most Recent Events

  • 16 Oct 2017 US District Court issued an adverse trial decision finding for the four asserted patents covering Cyclosporine ophthalmic in USA
  • 12 Oct 2017 Allergan enters into settlement agreement with InnoPharma related to Hatch-Waxman litigation for generic launch in USA
  • 11 Sep 2017 Allergan in-licenses Orange Book patents for Ciclosporin ophthalmic from The Saint Regis Mohawk Tribe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top